This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

WuXi AppTec Completes Acquisition of OXGENE to Strengthen Cell & Gene Therapy Service Offerings

WuXi AppTec Completes Acquisition of OXGENE to Strengthen Cell & Gene Therapy Service Offerings

02 Mar 2021

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers PHILADELPHIA and OXFORD, March 2, 2021 – WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract... Read more

Oxular raises $37 million – Led by specialist life sciences investor, Forbion

Oxular raises $37 million – Led by specialist life sciences investor, Forbion

01 Mar 2021

Investment will fund Phase 2 human clinical studies evaluating Oxular’s 12-month treatment for diabetic macular edema, and accelerate development of early-product pipeline OXFORD, UK, 1 March 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announced that it has completed a $37 million (£27 million) financing led by Forbion. Proceeds will fund planned... Read more

Evox Therapeutics completes £69.2 million Series C financing

Evox Therapeutics completes £69.2 million Series C financing

18 Feb 2021

18th Feb 2021 Financing round significantly oversubscribed by both new and existing investors Proceeds enable advancement of our exosome therapeutics into the clinic and expansion of our world-leading exosome platform Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round. The financing was... Read more

Exscientia & University of Oxford announce partnership to develop treatments for Alzheimer’s disease

Exscientia & University of Oxford announce partnership to develop treatments for Alzheimer’s disease

11 Feb 2021

Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer’s disease medicines that alleviate the burden of devastating disease  Oxford: Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease... Read more

Immunocore Announces Pricing of Upsized Initial Public Offering

Immunocore Announces Pricing of Upsized Initial Public Offering

05 Feb 2021

Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the pricing of its upsized initial public offering in the United States of 9,935,896American Depositary Shares (“ADSs”) representing 9,935,896 ordinary shares at an... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More